Clinical Trial: Blinatumomab Combined With Venetoclax as Maintenance Therapy After Allo-HSCT in High-risk Ph Negative Acute B-cell Lymphoblastic Leukemia

U.S., Oct. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07199855) titled 'Blinatumomab Combined With Venetoclax as Maintenance Therapy After Allo-HSCT in High-risk Ph Negative Acute B-cell Lymphoblastic Leukemia' on Sept. 09.

Brief Summary: This study is a single-center, single-arm, prospective clinical trial evaluating the efficacy and safety of blinatumomab combined with venetoclax as maintenance therapy for high-risk Philadelphia chromosome-negative acute B-cell lymphoblastic leukemia (B-ALL) after allogeneic hematopoietic stem cell transplantation .

Study Start Date: June 01

Study Type: INTERVENTIONAL

Condition: B-Cell Acute Lymphoblastic Leukemia, Adult

Intervention: DRUG: blinatumomab combined ...